small integral membrane protein 3Genealiases: C5orf62 · MST150 · NID67
Q-omics provides the consensus-scored SMIM3 profile across patient tissues and cancer cell-line models. SMIM3 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SMIM3 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, SMIM3 RNA expression shows 23,153 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, HNSC, and LSCC as cancer lineages where SMIM3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMIM3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMIM3 survival associations across molecular data types. SMIM3 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMIM3 RNA expression–survival associations across cancer types. High SMIM3 expression shows unfavorable associations in MESO, LGG, LUSC and STAD, but favorable associations in ACC and LUAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SMIM3 RNA expression.
This table summarizes SMIM3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SMIM3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMIM3 shows lower tumor expression in KICH and BRCA and higher tumor expression in HNSC, KIRC, COAD and THCA. The HNSC box plot shows higher SMIM3 RNA expression in tumor versus normal tissue (log2 FC = +1.905, t-test p < 0.001).
This table shows molecular features associated with SMIM3 in patient tissues and cancer cell lines. In patient samples, SMIM3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SMIM3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in CNS and SOFT_TISSUE.
